If you have been treating HS like a skin condition, you have been treating the wrong problem.
The lesions are not the problem. They are the signal.
Most patients reach EPOH after years of treatments that addressed the symptom, never the source.
Does this sound familiar?
This is not a failure of willpower. It is a predictable result of treating the wrong layer.
Why it keeps happening
The lesions are the output, not the problem. Beneath every recurring boil and sinus tract, five internal systems have lost coordination — and until they are addressed together, the skin cannot recover.
Five interconnected systems:
Each system feeds into the others. No two patients share the same profile — which is why the EPOH evaluation starts with identifying which systems dominate in your case.
A Note of Clarity
Remission in HS does not always mean complete absence of lesions. It means the disease no longer controls your daily life.
For many long-standing cases, this is a clinically meaningful and achievable outcome.
This is the foundation of the EPOH HS Protocol™
The 5-System HS Framework
Gut Dysfunction
Weakened digestion → inflammatory toxin buildup → immune activation
Hormonal Imbalance
Androgen excess, insulin resistance, PCOS link — drives follicular activity
Immune Dysregulation
Overactive inflammatory response — misfiring immune signalling
Metabolic Disruption
Systemic metabolic load sustains the inflammatory cycle
Tissue & Lymphatic Vulnerability
Follicular blockage and poor drainage — the recurring HS sites
All five systems interact. Single-system treatment produces incomplete results — this is why HS keeps returning.
A structured 5-phase system designed to move HS from active inflammation to sustained remission. Each phase builds on the last — skipping phases is why most approaches produce temporary results.
Before healing can begin, the existing cycle of inflammation must be interrupted. This phase focuses on reducing the active inflammatory burden — cooling the internal fire that sustains lesion formation.
Outcome
Reduced flare frequency and lower inflammatory burden.
Gut health, hormonal balance, and metabolic function are addressed in a specific sequence. The internal drivers identified in evaluation become the targets. Personalisation is highest in this phase.
Outcome
Stabilised gut function and recalibrated immune response.
Accumulated inflammatory toxins are systematically cleared through enhanced elimination pathways. This is not a generic cleanse — it is targeted removal of the specific toxin load identified in each patient.
Outcome
Cleared accumulated load — immune system no longer in overdrive.
Once internal correction is underway, attention turns to the damaged tissue — healing sinus tracts, reducing scarring, and restoring the structural integrity of the skin and follicular environment.
Outcome
Active lesion management with targeted local correction.
The final phase builds long-term resilience. Immunity is strengthened, lifestyle alignment is established, and the conditions that originally allowed HS to develop are systematically removed.
Outcome
Long-term resilience. The condition no longer controls daily life.
Honest framing — because the right fit matters more than a wider net.
EPOH is not the right starting point for every patient. Understanding who benefits most prevents wasted time and sets clear expectations from the beginning.
Most patients who benefit have been dealing with HS for 3–10 years and have not found lasting relief through conventional treatment.
If you are in an acute crisis, please seek emergency care first. EPOH works best as a structured, long-term approach — not crisis management.
Representative patterns — recurring combinations of history, triggers, and disease behaviour appearing consistently across patients.
Lesions worsening 7–10 days before menstruation. Multiple antibiotic courses. Hormones never formally evaluated. Gut symptoms present but dismissed.
Hormonal and gut axes addressed together. Flare frequency significantly reduced in 4–6 months.
Two excisions in three years. New lesions adjacent to healed sites. Metabolic indicators unaddressed. Antibiotics no longer effective.
Metabolic correction targeted. No new surgical lesions during treatment period.
Recurring nodules for 18 months. No surgery yet. Stress-linked pattern. Gut health poor. Seeking root-cause understanding before the condition advances.
Early-stage treatment most responsive. Lesion frequency reduced within 8 weeks.
Clinical note: These patterns are illustrative, not predictive. Individual response to treatment varies based on disease stage, duration, and systemic profile. Results are not guaranteed. A personalised evaluation is required before any treatment approach is determined.
A structured evaluation identifies which internal systems are driving your condition — and what a personalised approach to correction would look like. This is not a consultation to sell a product. It is a clinical conversation about your specific pattern.
EPOH · Dr. Adil Moulanchikkal, BAMS · +91 88847 22246 · Personalised evaluation required before treatment commences
HS does not remain static. Without internal correction, the disease follows a predictable trajectory — from isolated nodules to interconnected tunnels to systemic involvement. Understanding this progression changes how treatment decisions are made.
Gut health is not peripheral to HS — in many patients, it is the primary driver of sustained inflammation. This article explains the mechanism by which gut dysfunction translates into repeated skin lesions.
Suppression — managing the flare — is not the same as correction. This article explains why treatment sequence matters more than treatment intensity, and why most approaches begin at the wrong layer.